Integra LifeSciences Holdings Corp. (NASDAQ:IART) shares reached a new 52-week high on Thursday . The stock traded as high as $85.45 and last traded at $85.41, with a volume of 102,560 shares traded. The stock had previously closed at $84.67.

Several research firms have recently weighed in on IART. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating and set a $79.00 price target on the stock in a report on Monday, May 2nd. Lake Street Capital increased their target price on Integra LifeSciences Holdings Corp. from $57.00 to $75.00 and gave the company a “hold” rating in a research note on Thursday, April 28th. Barclays PLC increased their target price on Integra LifeSciences Holdings Corp. from $70.00 to $74.00 and gave the company an “equal weight” rating in a research note on Thursday, April 28th. JPMorgan Chase & Co. initiated coverage on Integra LifeSciences Holdings Corp. in a research note on Wednesday, July 13th. They issued an “overweight” rating on the stock. Finally, Jefferies Group increased their target price on Integra LifeSciences Holdings Corp. from $81.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, July 29th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $81.75.

The stock’s 50 day moving average is $81.87 and its 200-day moving average is $71.29. The firm has a market capitalization of $3.19 billion and a price-to-earnings ratio of 352.52.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.79 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.03. During the same quarter in the prior year, the business earned $0.79 EPS. The business had revenue of $249.30 million for the quarter, compared to analysts’ expectations of $243.17 million. The company’s revenue was up 17.2% compared to the same quarter last year. Equities research analysts anticipate that Integra LifeSciences Holdings Corp. will post $3.48 EPS for the current year.

In related news, CEO Peter J. Arduini sold 24,009 shares of Integra LifeSciences Holdings Corp. stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $84.52, for a total transaction of $2,029,240.68. Following the transaction, the chief executive officer now owns 29,602 shares in the company, valued at approximately $2,501,961.04. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Raymond G. Murphy sold 2,610 shares of Integra LifeSciences Holdings Corp. stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $84.83, for a total transaction of $221,406.30. Following the transaction, the director now owns 33,057 shares in the company, valued at approximately $2,804,225.31. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. State of Tennessee Treasury Department purchased a new position in Integra LifeSciences Holdings Corp. during the fourth quarter worth $1,501,000. Foresters Investment Management Company Inc. purchased a new position in Integra LifeSciences Holdings Corp. during the fourth quarter worth $5,050,000. Principal Financial Group Inc. boosted its position in Integra LifeSciences Holdings Corp. by 7.0% in the fourth quarter. Principal Financial Group Inc. now owns 196,763 shares of the company’s stock worth $13,337,000 after buying an additional 12,904 shares during the period. Westfield Capital Management Co. LP boosted its position in Integra LifeSciences Holdings Corp. by 41.7% in the fourth quarter. Westfield Capital Management Co. LP now owns 432,445 shares of the company’s stock worth $29,311,000 after buying an additional 127,170 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in Integra LifeSciences Holdings Corp. by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 928,232 shares of the company’s stock worth $62,916,000 after buying an additional 11,339 shares during the period.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.